Quantcast
Last updated on April 24, 2014 at 11:03 EDT

Latest Biogen Idec Stories

2013-08-07 08:30:31

CereKin(TM) (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, Aug. 7, 2013 /PRNewswire/ -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has initiated a pivotal clinical trial for CereKin(TM) (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of...

2013-07-24 08:30:18

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, July 24, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Illumina, Inc. (NASDAQ: ILMN), Santarus, Inc. (NASDAQ: SNTS), Celsion Corporation (NASDAQ: CLSN), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-07-17 04:20:59

LONDON, July 17, 2013 /PRNewswire/ -- The global pharmaceutical industry is facing many challenges and uncertainties as companies strive to align their businesses with the key trends shaping the global marketplace. Revenues are coming under increasing pressure as a consequence of pricing controls caused by healthcare reforms and austerity measures, increased competition, and challenges in bringing new drugs and other products to market. So, what are the most important...

2013-07-11 08:29:51

Tecfidera's High Early Physician Trial Rate Surpasses that Observed With Novartis's Gilenya and Genzyme's Aubagio, According to a New Report from BioTrends Research Group EXTON, Pa., July 11, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, despite being the third oral disease-modifying therapy (DMT) to launch in the U.S. multiple sclerosis (MS) market, 53 percent of surveyed...

2013-06-27 12:27:52

SEATTLE, June 27, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has signed an agreement with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive's proprietary immune profiling assay, immunoSEQ, will be used to characterize the immune repertoire of patient samples with...

2013-06-17 08:26:31

CAMBRIDGE, Mass., June 17, 2013 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) will hold its 11(th) annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with the mission to end amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO) Beginning in Newton, MA, the Tri-State Trek passes through 46...

2013-06-11 12:29:04

IF ELAN STOCKHOLDERS APPROVE ANY OF THE FOUR PROPOSED TRANSACTIONS, ROYALTY PHARMA WILL BE REQUIRED TO LAPSE ITS OFFER(I),(II) NEW YORK, June 11, 2013 /PRNewswire/ -- Royalty Pharma today announced that it believes Elan's (NYSE: ELN) disclosure in its May 27( )EGM Circular is misleading and inadequate, in Royalty Pharma's view, because it fails to: Regarding the entire package of proposed transactions: disclose that the Theravance, AOP, Speranza and inconsequential...

2013-06-11 08:30:59

LA JOLLA, Calif., June 11, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has named Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors effective immediately. Dr. Papadopoulos assumes the role of Chairman of the Board from John Maraganore, Ph.D., who will remain a member of the Board of Directors. Dr. Papadopoulos, who has been...

2013-06-10 08:29:10

ADS Shareholders Have Only Three Days to Vote NEW YORK, June 10, 2013 /PRNewswire/ -- Royalty Pharma today urged Elan Corporation, plc (NYSE: ELN) Shareholders to immediately vote AGAINST ALL FOUR resolutions Elan's Board has put forth for the Extraordinary General Meeting ("Elan EGM") on June 17. To meet the official voting deadlines: Holders of Elan American Depository Receipts held in street name may only vote their proxies through BroadRidge up to 11:59 PM New York time...

2013-06-07 08:24:15

CVR Allows Shareholders to Participate in Tysabri Royalty Upside for all Indications and Cash Flows, Pre- and Post-Patent Expiration NEW YORK, June 7, 2013 /PRNewswire/ -- Royalty Pharma today announced, pursuant to Rule 2.5 of the Irish Takeover Rules (the "Announcement"), a firm intention to further increase its offer for Elan Corporation, plc (NYSE: ELN) to $13.00 per share in cash plus a contingent value right ("CVR") worth up to $2.50 per share. The CVR, based on feedback...